Announcement on the Placement of Shares by Subsidiary Kelun-Biotech under General Authorization

Sichuan Kelun Pharmaceutical Co., Ltd.·July 8, 2026·2 pages

✨ AI Summary

Kelun Pharmaceutical's subsidiary, Kelun-Biotech, will place 5.838 million H shares at HK$470.20 per share to raise HK$2.723 billion. Funds will support R&D, internal capabilities, and working capital. This placement is expected to positively impact the company's long-term development.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Stock Code: 002422

Stock Abbreviation: Kelun Pharmaceutical

Announcement No.: 2026-051

Sichuan Kelun Pharmaceutical Co., Ltd.

Announcement on the Placement of Shares by Subsidiary Kelun-Biotech under General Authorization

The Company and the Board of Directors guarantee the truthfulness, accuracy, and completeness of the information disclosed, and that there are no false records, misleading statements, or material omissions.

Special Risk Warning:

The completion of this placement is subject to the fulfillment of certain conditions precedent stipulated in the placement agreement. The uncertainty of whether and when it will be completed warrants investors' attention to investment risks.

Sichuan Kelun Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") recently learned that its controlling subsidiary, S

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.